<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596193</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20010247H</org_study_id>
    <nct_id>NCT00596193</nct_id>
  </id_info>
  <brief_title>Neuropeptide Y (NPY) Regulation of Nociceptors</brief_title>
  <official_title>NPY Regulation of Nociceptors in Clinical Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuropeptide Y (NPY) potently inhibits pain neurons in rats, but does this occur in human&#xD;
      pain neurons? This hypothesis will be tested using microdialysis probes in patients who elect&#xD;
      to have root canal treatment or extraction of thier tooth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ongoing studies in rats indicate that a sympathetically-derived neuropeptide,&#xD;
      neuropeptide Y (NPY), potently inhibits the activity of the capsaicin-sensative class of&#xD;
      nociceptors (i.e., &quot;pain&quot; neurons). It is not know whether these results, generated from&#xD;
      rodent studies, occur in human tissues under normal or inflamed conditions. We plan to test&#xD;
      the hypothesis that NPY inhibits the initiation of neurogenic inflammation, as measured by&#xD;
      reduced release of substance P, from capsaicin-sensitive class of petidergic neurons&#xD;
      innervating normal and inflamed dental pulp. Such actions would be physiologically and&#xD;
      clinically significant, since inhibition of exocytosis from peripheral terminals of&#xD;
      nociceptive primary afferent fibers would likely alter neurogenic inflammation, local&#xD;
      vasodilation and , possibly pain. Our research strategy takes advantage of a uniquely&#xD;
      innervated tissue: dental pulp. Application of any physiologic stimulus to human dental pulp,&#xD;
      including thermal, osmotic, chemical or mechanical, produces only pain. Thus, virtually all&#xD;
      sensory neurons that innervate pulp appear to be nociceptors. Accordingly, application of&#xD;
      drugs to pulpal sensory neurons targets a population of sensory neurons consisting&#xD;
      predominantly of nociceptors.&#xD;
&#xD;
      The research questions are as follows:&#xD;
&#xD;
        1. Determine the capsaicin concentration-response curve from evoking the release of&#xD;
           immunioreactive substance P (iSP) from normal and inflamed dental pulp.&#xD;
&#xD;
        2. Determine the effect of NPY on altering basal and capsaisin-evoked release of iSP from&#xD;
           normal and inflamed dental pulp.&#xD;
&#xD;
      We will evaluate the hypothesis that NPY inhibits capsaicin-sensitive neurons in humans using&#xD;
      microdialysis probes implanted into anesthetized dental pulp, with release of immunoreactive&#xD;
      substance P (iSP) as our dependent measure. This study will include patients who have elected&#xD;
      to have a root canal procedure performed or to have a tooth extracted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <description>patients with normal or irreversible pulpitis teeth with capsaicin administered at increasing volumes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <description>Patients with normal teeth only with capsaicin added at a specific volume only</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Dental Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  teeth with diagnosis of normal pulp or irreversible pulpitis&#xD;
&#xD;
          -  mandibular teeth&#xD;
&#xD;
          -  indication for either root canal or extraction of tooth&#xD;
&#xD;
          -  age between 18-50&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of taking steroids within the last month&#xD;
&#xD;
          -  history of hyperthyroidism, hypertension, asthma, uncontrolled or complicated Type-2&#xD;
             diabetes, drug abuse&#xD;
&#xD;
          -  age less than 18 or greater than 50&#xD;
&#xD;
          -  maxillary teeth&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth M Hargreaves, DDS,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Kenneth Hargreaves</investigator_full_name>
    <investigator_title>Chair, Dept. of Endodontics</investigator_title>
  </responsible_party>
  <keyword>Hyperalgesia</keyword>
  <keyword>nociceptors</keyword>
  <keyword>Neurons</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

